Next Generation News and Research

RSS

Market for personalized medicine in the United States to grow 11 percent annually, shows report

The market for personalized medicine in the United States is already $232 billion, and it is projected to grow 11 percent annually, according to a new report published today by PricewaterhouseCoopers LLP, entitled The Science of Personalized Medicine: Translating the Promise into Practice.

8 Dec 2009

BD Diagnostics receives FDA clearance on Amplified DNA Assays

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received clearance from the U.S. Food and Drug Administration (FDA) to utilize its BD ProbeTec(TM) Chlamydia trachomatis (CT) Qx and BD ProbeTec(TM) Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected during women's routine liquid-based Pap testing for cervical cancer screening.

From BD (Becton, Dickinson and Company) 8 Dec 2009

ATS Medical's ATS 3f Enable Aortic Bioprosthesis receives European CE Mark approval

ATS Medical, Inc., manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced it has received CE Mark approval to distribute the ATS 3f Enable® Aortic Bioprosthesis in the European Union, indicating it is compliant with relevant European health, safety, and environmental protection legislation.

7 Dec 2009

SU2C awards $9.68 million to support high-risk cancer research

Stand Up To Cancer (SU2C) announced today that it is awarding $9.68 million to support high-risk/high-reward cancer research conducted by 13 young scientists.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

New data from PharmAthene's anthrax vaccine program presented

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees C.

5 Dec 2009

Hospira launches VisIV containers for intravenous medications and solutions

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL VisIV(TM) containers for intravenous (I.V.) medications and solutions, and now offers a complete size range (50 mL to 1 L) of the award-winning, environmentally responsible VisIV product.

5 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.

4 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its next-generation MultiSteering Technology software for Rapid Programmer™, a programming platform used to optimize neurostimulation therapy for chronic pain patients.

4 Dec 2009

Ambry Genetics and SoftGenetics sign agreement for next-generation sequencing projects at Ambry

Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics' NextGENe software for next-generation sequencing projects performed at Ambry.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

GTSI named value-added reseller of the Intel Health Guide RPM solution

GTSI Corp. an enterprise technology solutions and services provider was recently named a value-added reseller to deliver the Intel® Health Guide, a comprehensive, next-generation remote patient monitoring (RPM) solution that combines an in-home patient device, the Intel Health Guide PHS6000, with the Intel® Care Management Suite, an online interface that allows clinicians to monitor patients and remotely manage care.

3 Dec 2009

CLC bio, imaGenes announce collaboration in high-throughput sequencing analyses

Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.

3 Dec 2009

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will participate in and present data at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) workshop and BARDA Industry Day taking place in Washington, DC Dec. 2-4, 2009.

2 Dec 2009

NuGEN Technologies launches its next generation Ovation RNA-Seq System

NuGEN Technologies, Inc., a pace-setter in genomic sample preparation, enters the next generation sequencing (NGS) market today with its Ovation RNA-Seq System, a revolutionary method of sample preparation that broadens research horizons with a more comprehensive representation of the transcriptome created from samples of a few hundred picograms.

2 Dec 2009

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, selected febit's Geniom® RT Analyzer to advance its biomedical research by proceeding targeted Next-Generation Sequencing (NGS), genome-wide single nucleotide polymorphism (SNP) and microRNA (miRNA) analysis.

2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Next Generation News and Research

Market for personalized medicine in the United States to grow 11 percent annually, shows report

BD Diagnostics receives FDA clearance on Amplified DNA Assays

ATS Medical's ATS 3f Enable Aortic Bioprosthesis receives European CE Mark approval

SU2C awards $9.68 million to support high-risk cancer research

Albert Einstein College of Medicine receives SU2C grant for cancer research

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

New data from PharmAthene's anthrax vaccine program presented

Hospira launches VisIV containers for intravenous medications and solutions

Preclinical data of Curis' HSP 90 inhibitor published

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

IMF to stage presentation on multiple myeloma at ASH annual meeting

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

Ambry Genetics and SoftGenetics sign agreement for next-generation sequencing projects at Ambry

Pfizer announces a $9M cancer research collaboration in British Columbia

GTSI named value-added reseller of the Intel Health Guide RPM solution

CLC bio, imaGenes announce collaboration in high-throughput sequencing analyses

PharmAthene to present its biological/ chemical weapons countermeasure program data at the HHS PHEMCE workshop

NuGEN Technologies launches its next generation Ovation RNA-Seq System

Cancer Genomic Microarray Facility selects febit's Geniom RT Analyzer to advance its biomedical research

Canadians with hemophilia A can use new treatment option, XYNTHA

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News